EUVIMEDEUVIMED entdecken
Crossref

Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer

Adhar Amritt, Abhilash Dagar, Adrija Ghosh, Arjun Maiti, Jaswin Raj, Sangeeta Hazarika, Ashish Datt Upadhyay, Jitendra K Meena, Abhinav Singhal, Aman Sharma, Jyoti Sharma, Akash Kumar und 3 weitere

Breast Cancer Research and Treatment · 2026-07 · 218 (1)

DOI: 10.1007/s10549-026-08021-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 10.07.2026. Verfasst von Adhar Amritt und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Radiosurgery, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Stereotactic ablative body radiation (SABR), combined with systemic therapy (ST), is increasingly used to improve survival in oligometastatic breast cancer (OMBC). METHODS: Patients with no brain or bone metastases on whole-body PET-CT received curative-intent local and systemic treatment, including SABR to metastatic site. Doses were: liver (45-50 Gy/5 fractions), peripheral lung (54 Gy/3fractions), central lung (60 Gy/8fractions), lymph nodes (30 Gy/3fractions), and peritoneal deposits (45 Gy/5fractions). Response was assessed at 3 months (RECIST v1.1); pain, gross tumour volume (GTV), planning target volume (PTV), and toxicity (CTCAE) were documented. RESULTS: From Dec 2021 to Mar 2025, 39 patients (42 sites; median age 47) were treated: liver (17), lung (14), nodes (5), other (6). At a median follow-up of 23.9 months, median PFS was 16.3 months (95% CI: 10.3-24.1); median OS was not reached; restricted mean OS for the cohort was 89.2 months. Twenty-eight patients were alive, 11 died, two were lost to follow-up. Subtypes included TNBC (36%) and HER2+ (33%), luminal B (23%). Univariate analysis showed older age, smaller PTV, and higher BED10 improved PFS; multivariate analysis confirmed age (HR 0.20, p = 0.006), PTV (HR 6.57, p = 0.001), and luminal subtype. Most common toxicity: grade 2 pain flare and hepatitis (10%). CONCLUSION: Curative-intent treatment with SABR for visceral OMBC offers promising survival outcomes. Molecular subtyping may aid treatment selection. CLINICAL TRIAL NUMBER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryBreast NeoplasmsHumansFemaleMiddle AgedAdultAgedCombined Modality TherapyTreatment OutcomePositron Emission Tomography Computed TomographyNeoplasm Metastasis

Stichwörter der Autor:innen

Breast cancerMetastasisOligo-metastasisStereotactic ablative body radiation (SABR)Visceral

Autor:innen und Institutionen

  • Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Bio-Statistics, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Preventive Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Nuclear Medicine, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Surgical Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, National Cancer Institute All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Supriya Mallick

Zitieren

APA

Amritt, A., Dagar, A., Ghosh, A., Maiti, A., Raj, J., Hazarika, S., Upadhyay, A. D., Meena, J. K., Singhal, A., Sharma, A., Sharma, J., Kumar, A., Mathur, S., Saikia, J., & Mallick, S. (2026). Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer. Breast Cancer Research and Treatment, 218(1). https://doi.org/10.1007/s10549-026-08021-4

Vancouver

Amritt A, Dagar A, Ghosh A, Maiti A, Raj J, Hazarika S, et al. Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer. Breast Cancer Research and Treatment. 2026;218(1). doi:10.1007/s10549-026-08021-4

BibTeX
@article{Amritt2026,
  author = {Amritt, Adhar and Dagar, Abhilash and Ghosh, Adrija and Maiti, Arjun and Raj, Jaswin and Hazarika, Sangeeta and Upadhyay, Ashish Datt and Meena, Jitendra K and Singhal, Abhinav and Sharma, Aman and Sharma, Jyoti and Kumar, Akash and Mathur, Sandeep and Saikia, Jyoutishman and Mallick, Supriya},
  title = {Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {218},
  number = {1},
  doi = {10.1007/s10549-026-08021-4}
}
Kostenlos starten →